nVerses Capital LLC Boosts Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

nVerses Capital LLC increased its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 18.2% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 2,600 shares of the company’s stock after buying an additional 400 shares during the quarter. nVerses Capital LLC’s holdings in Amphastar Pharmaceuticals were worth $126,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Silvercrest Asset Management Group LLC grew its stake in shares of Amphastar Pharmaceuticals by 35.1% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 112,428 shares of the company’s stock worth $4,937,000 after buying an additional 29,182 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Amphastar Pharmaceuticals by 61.9% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 64,564 shares of the company’s stock worth $2,835,000 after buying an additional 24,678 shares during the last quarter. Intech Investment Management LLC purchased a new stake in shares of Amphastar Pharmaceuticals in the 2nd quarter worth approximately $426,000. Nordea Investment Management AB boosted its stake in Amphastar Pharmaceuticals by 0.4% during the 1st quarter. Nordea Investment Management AB now owns 333,014 shares of the company’s stock valued at $14,802,000 after purchasing an additional 1,209 shares during the last quarter. Finally, Granite Investment Partners LLC increased its holdings in shares of Amphastar Pharmaceuticals by 12.7% in the 2nd quarter. Granite Investment Partners LLC now owns 397,514 shares of the company’s stock worth $15,901,000 after purchasing an additional 44,744 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 10,282 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $44.23, for a total transaction of $454,772.86. Following the completion of the sale, the chief financial officer now owns 94,103 shares of the company’s stock, valued at approximately $4,162,175.69. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 10,282 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $44.23, for a total transaction of $454,772.86. Following the completion of the sale, the chief financial officer now owns 94,103 shares of the company’s stock, valued at approximately $4,162,175.69. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Richard K. Prins sold 17,101 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $43.07, for a total value of $736,540.07. Following the sale, the director now directly owns 33,971 shares of the company’s stock, valued at $1,463,130.97. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 34,383 shares of company stock valued at $1,524,123. Company insiders own 27.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on AMPH shares. StockNews.com raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Finally, Piper Sandler reduced their target price on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, Amphastar Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $63.00.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH opened at $50.84 on Monday. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.52 and a quick ratio of 2.63. Amphastar Pharmaceuticals, Inc. has a one year low of $36.56 and a one year high of $65.92. The firm has a market capitalization of $2.49 billion, a P/E ratio of 17.59, a PEG ratio of 0.88 and a beta of 0.83. The business has a fifty day moving average of $47.27 and a 200 day moving average of $43.19.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.75 by $0.10. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. The company had revenue of $182.39 million during the quarter, compared to analyst estimates of $171.29 million. As a group, sell-side analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.71 EPS for the current year.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.